Editorial: innovative therapeutic approaches for the treatment of pediatric autoimmune and inflammatory diseases. Curr Pharm Des 2012;18(35):5728.
. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7(6):e39543.
. The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clin Nutr 2012;31(6):1018-21.
. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.
. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs 2012;30(1):405-7.
. JCV+ Patients with Inflammatory bowel disease show elevated plasma levels of MIG and SCF. Inflamm Bowel Dis 2012;18(6):1194-6.
. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.
. The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum Immunol 2012;73(4):342-5.
. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55(4):367-9.
. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs 2012;30(2):803-7.
. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.
. Potential role of TRAIL in the management of autoimmune diabetes mellitus. Curr Pharm Des 2012;18(35):5759-65.
.